Pfizer shares dropped sharply on Tuesday after the company’s 2022 sales guidance appeared to fall short of expectations.
The guidance that Pfizer (ticker: PFE) presented, however, doesn’t take into account future sales of Pfizer’s Covid-19 vaccine and antiviral, but only sales already made. The number will likely climb upward as the year progresses, suggesting that the selloff on Tuesday may have been based on a misunderstanding.
In…